Using genomic data to guide treatment for rare childhood cancers

Rare childhood cancers often resist simple classification. A tumour may appear under a familiar diagnosis while carrying molecular features that affect its growth, response to therapy, or risk of relapse. Genomic medicine adds another layer of evidence by examining the DNA, RNA, and sometimes epigenetic patterns within a child’s cancer.

For families, this approach can clarify an uncertain diagnosis and identify treatment options when standard protocols are limited. For clinicians and researchers, it creates a pathway to connect laboratory discoveries with decisions made in paediatric oncology services.

Genomic testing does not replace experienced clinical care. Its value comes from combining molecular findings with the child’s age, symptoms, imaging, pathology, previous treatment, family history, and preferences. Careful interpretation is essential when evidence is limited or a result has no established treatment attached to it.

Why molecular information matters in paediatric oncology

Traditional diagnosis relies on the tumour’s appearance under a microscope, its location, and clinical behaviour. These details remain important, but two cancers that look similar can be driven by different genetic changes. Conversely, tumours in different organs may share a molecular alteration and respond to related medicines.

Testing can identify changes in genes that control cell division, DNA repair, immune signalling, or the movement of cancer cells. It may also reveal gene fusions, copy-number changes, mutations, or methylation patterns that refine the tumour classification. This is particularly useful for rare cancers, where the initial diagnosis may be based on a small number of cases and limited clinical experience.

A more precise diagnosis can influence the choice of chemotherapy, targeted therapy, immunotherapy, radiotherapy, or surgery. It can also help clinicians avoid treatments that are unlikely to work, although genomic results must be interpreted alongside clinical trial evidence and known risks.

From a tumour sample to a usable result

The process begins with obtaining a suitable sample, usually from a biopsy or surgical procedure. A pathology team confirms that the specimen contains enough tumour tissue and that testing will be technically reliable. In some cases, an earlier sample may be reviewed because a stored specimen can provide valuable information.

Sequencing may examine a focused panel of cancer-related genes, a larger portion of the tumour genome, or nearly all coding regions. RNA analysis can detect abnormal gene fusions that DNA testing might miss, while methylation profiling can help distinguish between tumour subtypes with similar appearances. Blood or saliva may be tested separately to identify inherited variants.

The laboratory report is only one part of the process. Molecular pathologists, oncologists, genetic counsellors, pharmacists, and researchers may review the findings through a multidisciplinary meeting. This protects families from receiving a long list of technical changes without a clear explanation of what each result means for care.

Understanding actionable and uncertain findings

A genomic alteration is considered actionable when there is credible evidence that it can guide diagnosis, treatment, monitoring, or genetic counselling. The strength of that evidence varies. A medicine may be approved for the child’s tumour type, supported by a relevant clinical trial, or used under a specialist program when no standard option exists.

Some results are potentially relevant but uncertain. A variant may affect a gene associated with cancer without proving that a particular drug will help. Other changes may be common in cancer cells but offer no practical treatment target. Families should be told clearly when a result is informative rather than immediately therapeutic.

Results can also change over time. A tumour may develop new alterations after treatment, and a sample taken from a relapse may differ from the original biopsy. Where clinically appropriate, repeat testing can explain treatment resistance or identify a new trial option.

Matching treatment to the child, not just the tumour

A promising molecular target does not automatically make a treatment suitable. Paediatric oncologists must consider the medicine’s toxicity, interactions with current therapy, effects on development, and the child’s overall condition. Dose, scheduling, formulation, and access may differ substantially from adult cancer care.

Clinical trials are often the safest route for testing a new treatment in a rare childhood cancer. A trial may evaluate a targeted drug across several tumour types that share a genomic feature, rather than enrolling children only according to the organ where the cancer began. This design can expand opportunities for children whose cancers are too uncommon for large conventional studies.

Genomic data can also support treatment planning beyond drug selection. It may help estimate relapse risk, identify a need for closer surveillance, or distinguish a condition that requires a different surgical or radiotherapy strategy. These decisions should be documented in a shared care plan that families can understand.

Protecting children and families through ethical care

Genomic testing can uncover inherited information that affects parents, siblings, and future relatives. Before testing, families should receive age-appropriate information about possible findings, privacy, data storage, and whether results may be reinterpreted as scientific knowledge develops. Children should be involved in decisions according to their maturity and capacity.

Equity is another central concern. Access to advanced sequencing, specialist interpretation, and relevant trials can vary by location, referral pathway, and financial resources. Families in regional and remote Queensland may need coordinated support for travel, sample handling, telehealth consultations, and follow-up care.

Research governance must protect participants while enabling responsible data sharing. De-identified genomic information can help researchers understand rare tumours and improve future treatment, but consent processes should explain how samples and data may be used. Clear governance builds trust between families, health services, universities, and research institutes.

Translating evidence into coordinated practice

Genomic medicine works best when it is part of a broader health translation system. Networks that connect clinicians, laboratories, universities, and consumers can help promising findings move from research projects into standardised care. The same principle applies across health conditions: clinical services benefit when evidence is adapted to local needs and evaluated in real settings.

Queensland’s research environment includes collaborative work on diagnosis, treatment, rehabilitation, and long-term outcomes. Resources such as health translation network information can help clinicians and communities understand how partnerships support research governance, education, funding, and implementation.

Translation also requires measurement. Services can track how often genomic testing changes diagnosis, treatment, trial referral, or family counselling. They can assess turnaround times, costs, adverse effects, patient experience, and whether benefits reach children from diverse communities. Lessons from personalised care in other fields, including tailored exercise interventions, show why local evidence and ongoing evaluation matter.

Practical priorities for a genomic care pathway

A reliable program should combine technical capability with communication and follow-up. The following priorities can help health services build a safer, more useful pathway:

• Establish referral criteria for children with rare, relapsed, treatment-resistant, or diagnostically uncertain cancers.
• Use multidisciplinary review to connect genomic findings with pathology, imaging, treatment history, and clinical trial options.
• Offer genetic counselling when testing may reveal inherited cancer susceptibility.
• Create processes for recording, reinterpreting, and communicating results as evidence changes.
• Measure access, turnaround time, treatment impact, family experience, and equity across metropolitan and regional services.

Families should receive a plain-language report that separates confirmed findings, possible implications, and unresolved uncertainty. They also need a named clinical contact who can explain the result and discuss whether additional testing, surveillance, or research participation is appropriate.

By linking genomic expertise with paediatric oncology, pathology, ethics, and community partnership, health services can make rare cancer care more precise without losing sight of the child behind the data. Continued collaboration across Queensland can turn individual molecular findings into knowledge that improves diagnosis, treatment, and survivorship for many families.